Hostname: page-component-745bb68f8f-lrblm Total loading time: 0 Render date: 2025-01-26T02:47:33.571Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of Sodium Valproate on Tardive Dyskinesia

Published online by Cambridge University Press:  29 January 2018

M. Linnoila ,
M. Viukari  and
O. Hietala
M. Linnoila*
Affiliation:
Department of Pharmacology, University of Helsinki, Helsinki, Finland
M. Viukari
Affiliation:
Koskela Geriatric Hospital, Helsinki, Finland
O. Hietala
Affiliation:
Nikkila Hospital, Sipoo, Finland
*
Address for correspondence: Markku Linnoila, M.D., Box 2921, Duke University Medical Center, Durham, N.C. 27710, USA.
Get access Rights & Permissions [Opens in a new window]

Summary

The effect of sodium valproate, a drug which has been demonstrated to increase gamma-aminobutyric acid levels in the CNS, on tardive dyskinesia and psychiatric symptoms was investigated in a double-blind cross-over study on 32 chronic psychiatric patients. The oro-facial dyskinesias were totally or significantly relieved in 17 cases. During the active treatment period the involuntary movements of the extremities and dystonic spasms were also significantly relieved in 7 out of 9 patients. In two patients, however, the extrapyramidal symptoms became slightly worse. A significant improvement was noted in the psychiatric symptoms of 14 out of 32 patients during sodium valproate administration. The psychiatric state of 4 out of 32 patients deteriorated. There was no correlation between the serum concentration of sodium valproate and its effect on the dyskinesia or on the psychiatric symptoms. Some of the elderly subjects showed a slight accumulation of the drug.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 129 , Issue 2 , August 1976 , pp. 114 - 119
Copyright
Copyright © Royal College of Psychiatrists, 1976 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bordeleau, J. M., Albert, J. M. & Hillet, J. (1967) Médication antiparkinsonienne et bilan extrapyramidal: étude du trihexyphenidyl. Canadian Psychiatric Association Journal, 12, 585–94.CrossRefGoogle Scholar
Crane, G. E. (1968) Tardive dyskinesias in patients treated with major neuroleptics: a review of the literature. American Journal of Psychiatry, 124 (Feb Suppl), 40–8.CrossRefGoogle ScholarPubMed
Crane, G. E. (1972) Prevention and management of tardive dyskinesia. American Journal of Psychiatry, 129, 126–7.CrossRefGoogle ScholarPubMed
Crane, G. E. (1973) Persistent dyskinesia. British Journal of Psychiatry, 122, 395–406.CrossRefGoogle ScholarPubMed
Crane, G. E. & Smeets, R. A. (1974) Tardive dyskinesia and drug therapy in geriatric patients. Archives of General Psychiatry, 30, 341–3.CrossRefGoogle ScholarPubMed
Fann, W. E., Gerber, C. J. & McKenzie, G. M. (1974) Cholinergic suppression of tardive dyskinesia. Psychopharmacologia, 37, 101–7.CrossRefGoogle ScholarPubMed
Fuxe, K., Hokfelt, T., Aquati, L. F., Ljungdahl, A., de la Mora, M. P. & Johansson, O. (1975) Further studies on the inhibitory control of mesolimbic dopamine neurons. Possibility of improving treatment of schizophrenia by combined treatment with neuroleptics and gabergic drugs. Abstracts of the 6th Intertional Meeting of Pharmacology, p 173. Helsinki, Finland, 1975.Google Scholar
Gerlach, J., Rebby, N. & Randrup, A. (1974) Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharrnacologia, 34, 21–35.CrossRefGoogle ScholarPubMed
Godin, Y., Heiner, L. & Mark, J. (1969) Effects of di-n-propylacetate, an anticonvulsive compound, on GABA metabolism. Journal of Neurochemistry, 16, 69–73.CrossRefGoogle ScholarPubMed
Hall, P. & Coleman, J. (1972) Flupenthixol in the treatment of schizophrenia. British Journal of Psychiatry, 120, 241–2.Google ScholarPubMed
Hippius, H. & Lange, J. (1970) Zur Problematic der späten extrapyramidalen Hyperkinesien nach langfristiger neuroleptischer Therapie. Arzneimittel Forschung, 20, 888–90.Google Scholar
Huskissson, E. C. & Wojtulewski, J. A. (1974) Measurement of side effects of drugs. British Medical Journal, ii, 698–9.Google Scholar
Jarvils, M. E. (1970) Drugs used in the treatment of psychiatric disorders. In The Pharmacological Basis of Therapeutics (eds. Goodman, L. S. and Gilman, A.), pp 151–203. New York: Macmillan.Google Scholar
Jeavons, P. M. & Clark, J. E. (1974) Sodium valproate in treatment of epilepsy. British Medical Journal, ii, 584–6.Google Scholar
Kazamazuri, H., Chien, C. & Cole, J. O. (1972) Therapeutic approaches to tardive dyskinesia. Archives of General Psychiatry, 27, 491–9.Google Scholar
Kazamazuri, H., Chien, C. & Cole, J. O. (1972) Treatment of tardive dyskinesia. Archives of General Psychiatry, 27, 100–3.Google Scholar
Kazamazuri, H., Chien, C. & Cole, J. O. (1973) Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. American Journal of Psychiatry, 130, 419–23.Google Scholar
Kiloh, L. G., Smith, J. S. & Williams, S. E. (1974) Antiparkinson drugs as causal agents in tardive dyskinesia. Medical Journal of Australia, 25, 591–3.Google Scholar
Klawans, H. L. Jr (1973) Pharmacology of tardive dyskinesias. American Journal of Psychiatry, 130, 82–6.CrossRefGoogle ScholarPubMed
Klawans, H. L. Jr (1968) The pharmacology of Parkinsonism. Diseases of the Nervous System, 29, 805–16.Google ScholarPubMed
Korezyn, A. D. (1972) Pathophysiology of drug-induced dyskinesias. Neuropharmacology, 11, 601–7.Google Scholar
Meijer, J. W. A. & Hessing-Brand, L. (1973) Determination of lower fatty acids, particularly the anticpileptic dipropyl-acetic acid, in biological materials by means of micro diffusion gas chromatography. Clinica Chimica Acta, 43, 215–22.CrossRefGoogle ScholarPubMed
Miller, E. (1974) Deanol in the treatment of levadopainduced dyskinesias. Neurology, 24, 116–19.CrossRefGoogle Scholar
Ohye, C., Bouchard, R. & Boucher, R. (1970) Spontaneous activity of the putamen after chronic interruption of the dopaminergic pathway: effect of L-dopa. Journal of Pharmacology and Experimental Therapeutics, 175, 700–8.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.CrossRefGoogle Scholar
Paulson, G. W. (1968) ‘Permanent’ or complex dyskinesias in the aged. Geriatrics, 23, 105–10.Google ScholarPubMed
Philippu, A. & Matthaei, H. (1975) Uptake of serotonin, gamma-aminobutyric acid and histamine into synaptic vesicles of the pig caudate nucleus. Naunyn-Schmiedeberg's Archives of Pharmacology, 287, 191–204.CrossRefGoogle ScholarPubMed
Ré, O. (1974) 2-dimemylaminoethanol: a brief review of its clinical efficacy and postulated mechanism of action. Current Therapeutic Research, 16, 1238–42.Google ScholarPubMed
Siegel, S. (1956) Nonparametric Statistics for Behavioral Sciences, p 75. New York: McGraw-Hill.Google Scholar
Stevens, J., Wilson, K. & Foote, W. (1974) GABA blockage, dopamine and schizophrenia: experimental studies in the cat. Psychopharmacologia, 39, 105–19.CrossRefGoogle Scholar
Sutor, A. H. & Jesdinsky-Buscher, C. (1974) Gerinnungs Veranderungen durch Dipropylessigsaure. Medizinische Welt, 25, 447–9.Google Scholar
Villeneuve, A., Lavalée, J. C. & Limieux, L. H. (1969) Dyskinésie tardive postneuroleptique. Laval Médical, 40, 832–7.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.